Biomarkers in amyotrophic lateral sclerosis: Combining metabolomic and clinical parameters to define disease progression

European Journal of Neurology

Volumn 23, Issue 2, 2016, Pages 346-353

  Blasco, H ^a,b   Nadal Desbarats, L ^a   Pradat, P F ^c   Gordon, P H ^d   Madji Hounoum, B ^a   Patin, F ^a   Veyrat Durebex, C ^a   Mavel, S ^a   Beltran, S ^b   Emond, P ^a   Andres, C R ^a,b   Corcia, P ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d Northern Navajo Medical Center   (United States)

Author keywords

1H NMR spectroscopy; Amyotrophic lateral sclerosis; Biomarkers; Metabolomics; Survival

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; AMYOTROPHIC LATERAL SCLEROSIS FUNCTIONAL RATING SCALE; ARTICLE; ASSESSMENT OF HUMANS; BODY WEIGHT; CEREBROSPINAL FLUID; CLINICAL STUDY; COHORT ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLITE; METABOLOMICS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTON NUCLEAR MAGNETIC RESONANCE; SURVIVAL TIME; TRAINING; METABOLOME; MIDDLE AGED; PHYSIOLOGY; PROGNOSIS;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; BIOMARKERS; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; METABOLOME; METABOLOMICS; MIDDLE AGED; PROGNOSIS; PROTON MAGNETIC RESONANCE SPECTROSCOPY;

EID: 84956574243     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12851     Document Type: Article

References (34)

1. Chio A, Logroscino G, Traynor BJ, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 2013; 41: 118-130.
2. Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 2013; 9: 617-628.
3. Gordon PH, Salachas F, Lacomblez L, et al. Predicting survival of patients with amyotrophic lateral sclerosis at presentation: a 15-year experience. Neurodegener Dis 2013; 12: 81-90.
4. Simon NG, Turner MR, Vucic S, et al. Quantifying disease progression in amyotrophic lateral sclerosis. Ann Neurol 2014; 76: 643-657.
5. Calvo AC, Manzano R, Mendonca DM, Munoz MJ, Zaragoza P, Osta R. Amyotrophic lateral sclerosis: a focus on disease progression. Biomed Res Int 2014; 2014: 925101.
6. Wuolikainen A, Andersen PM, Moritz T, Marklund SL, Antti H. ALS patients with mutations in the SOD1 gene have a unique metabolomic profile in the cerebrospinal fluid compared with ALS patients without mutations. Mol Genet Metab 2012; 105: 472-478.
7. Wuolikainen A, Moritz T, Marklund SL, Antti H, Andersen PM. Disease-related changes in the cerebrospinal fluid metabolome in amyotrophic lateral sclerosis detected by GC/TOFMS. PLoS One 2011; 6: e17947.
8. 1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosis. PLoS One 2010; 5: e13223.
9. Blasco H, Corcia P, Pradat PF, et al. Metabolomics in cerebrospinal fluid of patients with amyotrophic lateral sclerosis: an untargeted approach via high-resolution mass spectrometry. J Proteome Res 2013; 12: 3746-3754.
10. 1H-NMR metabolomics in CSF: toward a diagnostic biomarker for motor neuron disease. Neurology 2014; 82: 1167-1174.
11. Otto M, Bowser R, Turner M, et al. Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotroph Lateral Scler 2012; 13: 1-10.
12. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 293-299.
13. Scotton WJ, Scott KM, Moore DH, et al. Prognostic categories for amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2012; 13: 502-508.
14. Su XW, Simmons Z, Mitchell RM, Kong L, Stephens HE, Connor JR. Biomarker-based predictive models for prognosis in amyotrophic lateral sclerosis. JAMA Neurol 2013; 70: 1505-1511.
15. Rooney J, Byrne S, Heverin M, et al. Survival analysis of Irish amyotrophic lateral sclerosis patients diagnosed from 1995-2010. PLoS One 2013; 8: e74733.
16. Gupta PK, Prabhakar S, Sharma S, Anand A. A predictive model for amyotrophic lateral sclerosis (ALS) diagnosis. J Neurol Sci 2012; 312: 68-72.
17. Gordon PH, Salachas F, Lacomblez L, et al. Predicting survival of patients with amyotrophic lateral sclerosis at presentation: a 15-year experience. Neurodegener Dis 2013; 12: 81-90.
18. Gordon PH, Corcia P, Lacomblez L, et al. Defining survival as an outcome measure in amyotrophic lateral sclerosis. Arch Neurol 2009; 66: 758-761.
19. Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995; 118(Pt 3): 707-719.
20. Reich-Slotky R, Andrews J, Cheng B, et al. Body mass index (BMI) as predictor of ALSFRS-R score decline in ALS patients. Amyotroph Lateral Scler Frontotemporal Degener 2013; 14: 212-216.
21. Ngo ST, Steyn FJ, McCombe PA. Body mass index and dietary intervention: implications for prognosis of amyotrophic lateral sclerosis. J Neurol Sci 2014; 340: 5-12.
22. Czaplinski A, Yen AA, Appel SH. Amyotrophic lateral sclerosis: early predictors of prolonged survival. J Neurol 2006; 253: 1428-1436.
23. Pupillo E, Messina P, Logroscino G, Beghi E. Long-term survival in amyotrophic lateral sclerosis: a population-based study. Ann Neurol 2014; 75: 287-297.
24. Dupuis L, Pradat PF, Ludolph AC, Loeffler JP. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol 2011; 10: 75-82.
25. Spreux-Varoquaux O, Bensimon G, Lacomblez L, et al. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J Neurol Sci 2002; 193: 73-78.
26. Rothstein JD, Tsai G, Kuncl RW, et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990; 28: 18-25.
27. Hutson SM, Lieth E, LaNoue KF. Function of leucine in excitatory neurotransmitter metabolism in the central nervous system. J Nutr 2001; 131: 846S-850S.
28. Contrusciere V, Paradisi S, Matteucci A, Malchiodi-Albedi F. Branched-chain amino acids induce neurotoxicity in rat cortical cultures. Neurotox Res 2010; 17: 392-398.
29. McLaurin J, Golomb R, Jurewicz A, Antel JP, Fraser PE. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta-induced toxicity. J Biol Chem 2000; 275: 18495-18502.
30. Grossman M, Elman L, McCluskey L, et al. Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis. JAMA Neurol 2014; 71: 442-448.
31. Dai Z, Wu Z, Yang Y, et al. Nitric oxide and energy metabolism in mammals. BioFactors 2013; 39: 383-391.
32. Harkness RA, McCreanor GM, Watts RW. Lesch-Nyhan syndrome and its pathogenesis: purine concentrations in plasma and urine with metabolite profiles in CSF. J Inherit Metab Dis 1988; 11: 239-252.
33. Abraham A, Drory VE. Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis. J Neurol 2014; 261: 1133-1138.
34. von Neuhoff N, Oumeraci T, Wolf T, et al. Monitoring CSF proteome alterations in amyotrophic lateral sclerosis: obstacles and perspectives in translating a novel marker panel to the clinic. PLoS One 2012; 7: e44401.